Last reviewed · How we verify
Tumor Tissue (tumor-tissue)
At a glance
| Generic name | tumor-tissue |
|---|---|
| Sponsor | Pfizer |
| Drug class | Not specified |
| Target | Not specified |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Anaplastic Large Cell Lymphoma
- Anaplastic Thyroid Carcinoma
- Basal Cell Carcinoma
- Blastoid Mantle Cell Lymphoma
- Breast Cancer
- Cervical Cancer
- Chordoma
- Chordoma, Chondroid
- Chordoma, Dedifferentiated
- Chordoma, Enchondroid
- Chordoma, Myxoid
- Chordoma, Not Otherwise Specified
- Chordoma, Papillary
- Chordoma, Squamous
- Chordoma, Squamous with Megakaryoblastic Differentiation
- Chordoma, Squamous with Rhabdoid Features
- Chordoma, Squamous with Spindle Cell Features
- Chordoma, Squamous with Undifferentiated Features
- Chordoma, Squamous with Undifferentiated Features and Rhabdoid Features
- Chordoma, Squamous with Undifferentiated Features and Spindle Cell Features
Pipeline indications
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Clopidogrel
- Pentoxifylline
- Dipyridamole
- Ticlopidine
- Alteplase
- Urokinase
- Streptokinase
- Tenecteplase
- Reteplase
- Abciximab
Key clinical trials
- Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (PHASE1)
- TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC (EARLY_PHASE1)
- Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
- Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer (PHASE1)
- Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tumor Tissue CI brief — competitive landscape report
- Tumor Tissue updates RSS · CI watch RSS
- Pfizer portfolio CI